NAXAPROSTENE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H32O4
Molecular Weight	396.5192
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)C3CCCCC3)[C@@]1([H])C\C(C2)=C\C4=CC(=CC=C4)C(O)=O

InChI

InChIKey=OINUMRGCICIETD-CGKNXJIZSA-N

InChI=1S/C25H32O4/c26-23(18-6-2-1-3-7-18)10-9-21-22-14-17(13-20(22)15-24(21)27)11-16-5-4-8-19(12-16)25(28)29/h4-5,8-12,18,20-24,26-27H,1-3,6-7,13-15H2,(H,28,29)/b10-9+,17-11+/t20-,21+,22-,23+,24+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25542069 | https://www.ncbi.nlm.nih.gov/pubmed/3096342

Naxaprostene (CG 4305) is a prostacyclin analogue, which causes concentration dependent inhibition of thrombocyte function. Naxaprostene is more selective for IP receptors and tends towards partial agonism. Naxaprostene prevented thrombotic arterial occlusion in rabbits.

Approval Year

PubMed

Title	Date	PubMed
Antithrombotic effects of the prostacyclin analogue naxaprostene after oral and intraduodenal application in rabbit carotid artery thrombosis.	1992	1632291

Sample Use Guides

In Vivo Use Guide

The antithrombotic efficacy of naxaprostene has been tested in rabbits with copper coil-induced carotid artery thrombosis. With oral pretreatment, 10 mg/kg naxaprostene prevented thrombotic arterial occlusion; with intraduodenal pretreatment the efficacy of naxaprostene was enhanced and 1 mg/kg was sufficient to exert an antithrombotic effect.

Route of Administration: Oral

In Vitro Use Guide

ADP-induced aggregation is inhibited 25% by 50 nmol/l CG 4305 (naxaprostene).

Name

Type

Language

NAXAPROSTENE

Official Name

English

naxaprostene [INN]

Common Name

English

.ALPHA.-((2E,3AS,4R,5R,6AS)-4-((1E,3S)-3-CYCLOHEXYL-3-HYDROXYPROPENYL)HEXAHYDRO-5-HYDROXY-2(1H)-PENTALENYLIDENE)-M-TOLUIC ACID

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C78568